Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower stroke (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
SGLT2i showed no clear difference in stroke (fatal or non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
DPP4i showed no clear difference in stroke (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: recurrent stroke (non‐fatal or fatal) compared with medical therapy (low certainty).
1 finding from 1 review
Long‐term ipsilateral stroke · patients undergoing carotid endarterectomy, whether the initial indication for endarterectomy was symptomatic or asymptomatic carotid…
It is very uncertain whether main comparison of patch angioplasty changes ipsilateral stroke (fatal or non‐fatal; haemorrhage or infarct)… compared with primary closure (very low certainty).
1 finding from 1 review
Incidence of other type of stroke (ischaemic or haemorrhagic): fatal or non‐fatal · stroke and/or TIA
1 finding from 1 review
Intervention not reported
Number of patients with recurrent stroke (fatal and non‐fatal) at 90 days and at 1 year · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) · stroke and/or TIA
It is very uncertain whether marine‐derived n‐3 fatty acids therapy changes recurrent events: fatal or non‐fatal (same type of stroke, i.e.… compared with no marine‐derived n‐3 fatty acids therapy (very low certainty).
1 finding from 1 review
Perioperative ipsilateral stroke (< 30 days) · patients undergoing carotid endarterectomy, whether the initial indication for endarterectomy was symptomatic or asymptomatic carotid…
It is very uncertain whether main comparison of patch angioplasty changes ipsilateral stroke (fatal or non‐fatal; haemorrhage or infarct)… compared with primary closure (very low certainty).
1 finding from 1 review
Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: composite of recurrent stroke (non‐fatal or… compared with medical therapy (low certainty).
1 finding from 1 review
Long‐term any stroke · patients undergoing carotid endarterectomy, whether the initial indication for endarterectomy was symptomatic or asymptomatic carotid…
It is very uncertain whether main comparison of patch angioplasty changes any stroke (fatal or non‐fatal; contralateral, ipsilateral or… compared with primary closure (very low certainty).
1 finding from 1 review
Stroke, myocardial infarction, or vascular death · stroke and/or TIA
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in major vascular event (composite of non‐fatal stroke, non‐fatal… compared with placebo or no treatment (high certainty).
1 finding from 1 review
Stroke · patients undergoing carotid endarterectomy, whether the initial indication for endarterectomy was symptomatic or asymptomatic carotid…
It is very uncertain whether main comparison of patch angioplasty changes any stroke (fatal or non‐fatal; contralateral, ipsilateral or… compared with primary closure (very low certainty).
1 finding from 1 review
Primary outcome measure: recurrent stroke (non‐fatal or fatal) stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: recurrent stroke (non‐fatal or fatal)… compared with medical therapy (low certainty).
1 finding from 1 review
Fatal/non‐fatal stroke in the territory of the treated vertebral artery stenosis(assessed after 30 days post‐randomisation to completion of · people with vertebral artery stenosis
Endovascular treat ment plus medical treatment showed no clear difference in fatal/non‐fatal stroke in the territory of the treated vertebral… compared with medical treatment alone (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of patients with all vascular events (stroke, MI, non‐fatal cardiac arrest, unstable angina requiring revascularisation, vascular death) at 90 days and at 1 year · patients with TIA or ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) stratified by the type of device ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: composite of recurrent stroke (non‐fatal or… compared with medical therapy (low certainty).
1 finding from 1 review